What is the primary concern associated with antiphospholipid syndrome in SLE patients?

The primary concern associated with antiphospholipid syndrome in patients with systemic lupus erythematosus (SLE) is the elevated risk of thrombosis. Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which can lead to an increased tendency to form blood clots in both veins and arteries. This hypercoagulable state significantly raises the risk of complications, such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction.

In SLE patients, the combination of autoimmune processes and the presence of antiphospholipid antibodies can exacerbate this risk, making it a critical concern for patient management and monitoring. Addressing and recognizing this risk is essential for preventing serious vascular complications and improving overall patient outcomes. Other symptoms associated with SLE, such as joint damage, skin lesions, or mental health issues, are relevant but do not carry the same immediate and potentially life-threatening implications that thrombosis does in the context of antiphospholipid syndrome.